Ac Immune Sa · NASDAQ:ACIU
Ac Immune Sa — Shareholder Meeting (April 2018)
26 slides from Ac Immune Sa's shareholder meeting presentation, Apr 27, 2018
Slide 1: Novel Therapeutics and Diagnostics for Alzheimer's and Other Neurodegenerative Diseases
NOVEL THERAPEUTICS AND DIAGNOSTICS FOR ALZHEIMER’S AND OTHER NEURODEGENERATIVE DISEASES © 2018 AC Immune. Not to be used or reproduced without permission. www.acimmune.com NASDAQ: ACIU | EGM | April 27, 2018
Slide 2: Disclaimer
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 1 Disclaimer This presentation may contain statements that constitute “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securitie
Slide 3: AC Immune
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 2 AC Immune
Slide 4: About AC Immune
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 3 About AC Immune ▪ Based at the EPFL campus in Lausanne, Switzerland ▪ Nasdaq listed in September, 2016 with net proceeds of USD 70.5 million ▪ Ticker symbol: Nasdaq: ACIU ▪ 57.4 million shares ou
Slide 5: Vision
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 4 Vision SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Morphomer TM Conformation - sensitive small molecules To become a global leader in precision medicine 1 of
Slide 6: AC Immune: a leader in neurodegenerative diseases
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 5 AC Immune: a leader in neurodegenerative diseases Investment highlights Large and growing neurodegenerative diseases market driven by significant unmet medical need 1 Proprietary technology platf
Slide 7: Precision medicine creates ultimate differentiation: 3-pillar approach
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 6 Precision medicine creates ultimate differentiation Business strategy: 3 - pillar approach Vision Alzheimer’s disease (AD) Non - AD Neuro - orphans Diagnostics Technology platforms Values ▪ Devel
Slide 8: Global disease mechanism of proteinopathies
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 7 Global disease mechanism of proteino - pathies Nucleus Affected cell Nucleus Healthy cell Nucleus Reverse misfolding Inhibit spreading Promote Disaggre - gation Prevent seeding Recipient cell Dua
Slide 9: Product-focused and highly versatile platforms drive growth
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 8 Product - focused and highly versatile platforms drive growth Technology platforms SupraAntigen TM Vaccines and antibodies specific to disease causing conformations Immunotherapy against conforma
Slide 10: AC Immune's robust pipeline
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 9 Driven by proprietary technology platforms AC Immune’s robust pipeline Biologics Diagnostics Small molecules Crenezumab (anti - Abeta antibody) treatment Product candidate Target Partner Discover
Slide 11: Early diagnosis translates into earlier treatment and better outcome
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 10 Early diagnosis translates into earlier treatment and better outcome Alzheimer’s disease treatment Genetic diagnosis Imaging diagnosis Clinical diagnosis Genetic diagnosis ▪ The future treatment
Slide 12: Agenda items and proposals of the Board
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 11 Agenda items and proposals of the Board of Directors
Slide 13: Agenda
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 12 Agenda 1. Election of Member to the Board of Directors 2. Election to the Compensation , Nomination & Corporate Governance Committee 3. Compensation for the newly elected Member of the Board of
Slide 14: Agenda item 1: Election of Member to the Board
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 13 Agenda item 1 ▪ The Board of Directors proposes the election of Douglas E. Williams as new member of the Board of Directors, until the end of the next ordinary General Meeting. Election of Membe
Slide 15: Douglas E. Williams
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 14 Douglas E. Williams
Slide 16: Douglas E. Williams
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 15 Douglas E. Williams ▪ President, CEO and member of Board of Directors (BoD) of Codiak BioSciences ▪ BoD member of : - Ironwood Pharmaceuticals - Ovid Pharmaceuticals ▪ Previously Biogen’s Execut
Slide 17: Agenda item 2: Election to the Compensation, Nomination & Corporate Governance Committee
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 16 Agenda item 2 ▪ The Board of Directors proposes the election of Douglas E. Williams as new member of the Compensation, Nomination & Corporate Governance Committee, until the end of the next ordi
Slide 18: Agenda item 3.a: Compensation for the newly elected Member
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 17 Agenda item 3 ▪ The Board of Directors proposes to hold the following separate votes on the compensation of the new member of the Board of Directors: 3.a Vote on Total Non - Performance - Relate
Slide 19: Agenda item 3.b: Equity for the new Member
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 18 Agenda item 3 ▪ The Board of Directors proposes to hold the following separate votes on the compensation of the new member of the Board of Directors: 3.b Vote on Equity for the new Member of the
Slide 20: Share Capital Increase
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 19 Share Capital Increase
Slide 21: Agenda item 4: Share Capital Increase background and rationale
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 20 Background Rationale Agenda item 4: Share Capital Increase ▪ Shareholder approval is required under Swiss law for a company to increase its share capital ▪ Previous timeline for increase of auth
Slide 22: Agenda item 4: Share Capital Increase
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 21 Agenda item 4 ▪ The Board of Directors intends to increase the share capital of the Company as the previous timeline for the increase of authorized capital expired on date 20 October 2017. This
Slide 23: Agenda item 4a: Share Capital Increase for Institutional Investors
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 22 Agenda item 4a ▪ The Board proposes accordingly an ordinary share capital increase for institutional investors as follows: a) the share capital of the Company is increased by way of an ordinary
Slide 24: Agenda item 4b: Share Capital Increase for Current Shareholders
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 23 Agenda item 4b ▪ As for logistical reasons current shareholders may not be able to participate in the ordinary share capital increase for institutional investors, the Board proposes an ordinary
Slide 25: Agenda item 4b (cont.)
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 24 Agenda item 4b ( cont .) ▪ As for logistical reasons current shareholders may not be able to participate in the ordinary share capital increase for institutional investors, the Board proposes an
Slide 26: We thank you for coming and your continued support
© 2018 AC Immune. Not to be used or reproduced without permission. NASDAQ: ACIU | EGM | April 27, 2018 25 We thank you for coming and your continued support .